Pre-Open Movers 12/11: (YMAB) (ENTX) (GPS) Higher; (OPK) (SFIX) (CAMP) Lower (more...)
Yangtze River Port and Logistics Limited (NASDAQ: YRIV) 27.1% HIGHER; recent short target sees upside.
Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) 26.5% HIGHER; a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a humanized bispecific GD2 antibody. It is anticipated that a Phase 1/2 clinical trial will soon be initiated to begin screening patients with relapsed/refractory neuroblastoma, high grade osteosarcoma and other GD2(+) solid tumors, where patients have relapsed or refractory disease that is resistant to standard therapy.
SeaChange International, Inc. (NASDAQ: SEAC) 23.6% LOWER; reported third quarter fiscal 2019 revenue of $18.6 million and a U.S. GAAP loss from operations of $2.5 million, or $0.07 per basic share, compared to third quarter fiscal 2018 revenue of $23.4 million and U.S. GAAP income from operations of $0.9 million, or $0.03 per fully diluted share.
Entera Bio Ltd. (Nasdaq: ENTX) 20% HIGHER; announced today that it has entered into a research collaboration and license agreement with Amgen in inflammatory disease and other serious illnesses. Entera will use its proprietary drug delivery platform to develop oral formulations for one preclinical large molecule program that Amgen has selected. Amgen also has an option to select up to two additional programs to include in the collaboration
Stitch Fix (NASDAQ: SFIX) 20.1% LOWER; reported Q1 EPS of $0.10, $0.07 better than the analyst estimate of $0.03. Revenue for the quarter came in at $366.2 million versus the consensus estimate of $357.97 million. Stitch Fix (NASDAQ: SFIX) sees Q2 revenue of $360-$368 million and adjusted EBITDA of $8-$12 million vs consensus revenue of $362 million. Stitch Fix (NASDAQ: SFIX) sees FY revenue of $1.49-$1.53 billion and adjusted EBITDA of $20-$40 million vs consensus revenue of $1.51 billion.
DSW, Inc. (NYSE: DSW) 15.7% HIGHER; reported Q3 EPS of $0.70, $0.19 better than the analyst estimate of $0.51. Revenue for the quarter came in at $833 million versus the consensus estimate of $794.36 million. Comparable sales increased 7.3% DSW, Inc. sees FY2018 EPS of $1.80-$1.90, versus the consensus of $1.72.
Calamp Corp. (NASDAQ: CAMP) 14% LOWER; Updated Q3 Guidance Misses Views
Ascena Retail Group (NASDAQ: ASNA) 11.7% HIGHER; reported Q1 EPS of $0.06, versus $0.00 reported last year. Revenue for the quarter came in at $1.59 billion versus the consensus estimate of $1.56 billion. Ascena Retail Group sees Q2 2019 EPS of ($0.25)-($0.15), versus the consensus of ($0.12). Ascena Retail Group sees Q2 2019 revenue of $1.675-1.705 billion, versus the consensus of $1.7 billion.
Casey's General Stores (NASDAQ: CASY) 7.6% LOWER; reported Q2 EPS of $1.80, $0.19 better than the analyst estimate of $1.61. Revenue for the quarter came in at $2.54 billion versus the consensus estimate of $2.54 billion.
Quanex (NYSE: NX) 6.8% LOWER; reported Q4 EPS of $0.22, $0.21 worse than the analyst estimate of $0.43. Revenue for the quarter came in at $244.1 million versus the consensus estimate of $246.16 million.
Zynga (NASDAQ: ZNGA) 3.3% HIGHER; Macquarie upgraded from Neutral to Outperform and raised its price target to $4.65 (from $4.00).
Ra Pharmaceuticals, Inc. (Nasdaq: RARX) 3.2% LOWER; Announced that it intends to offer and sell, subject to market and other conditions, $100 million of its common stock in an underwritten public offering. Ra Pharma expects to grant the underwriters a 30-day option to purchase up to $15 million of additional shares of its common stock.
HCP, Inc. (NYSE: HCP) 2.7% LOWER; commenced a public offering of an aggregate of 14,000,000 shares of its common stock, consisting of 2,000,000 shares offered directly by the Company and 12,000,000 shares offered on a forward basis in connection with the forward sale agreement described below. The forward purchaser (as described below) expects to grant the underwriters a 30-day option to purchase up to an additional 2,100,000 shares of the Company's common stock.